ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
0.4132 USD   -7.73%
05/19ADAMIS PHARMACEUTICALS CORP : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/18Adamis Pharmaceuticals Appoints Chief Business Officer David Marguglio as CEO
MT
05/18Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société ADAMIS PHARMACEUTICALS CORPORATION
05/19ADAMIS PHARMACEUTICALS CORP : Entry into a Material Definitive Agreement, Change in Direct..
AQ
05/18Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovati..
AQ
05/16ADAMIS : Q1 Earnings Snapshot
AQ
05/16ADAMIS PHARMACEUTICALS CORP Management's Discussion and Analysis of Financial Conditio..
AQ
05/16Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corpor..
AQ
05/09Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call a..
AQ
05/09ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
04/11ADAMIS PHARMACEUTICALS CORP : Change in Directors or Principal Officers, Financial Stateme..
AQ
04/01US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI Naloxone Product
AQ
03/31ADAMIS PHARMACEUTICALS : Reports Full Year 2021 Financial Results and Provides Corporate U..
PU
03/31ADAMIS PHARMACEUTICALS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
03/31Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate ..
AQ
03/31US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone P..
GL
03/28ADAMIS PHARMACEUTICALS : Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Inje..
PU
03/28ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
03/24Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Co..
AQ
03/22Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI (epine..
AQ
03/22Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamste..
AQ
03/21Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epin..
AQ
03/14Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treat..
AQ
03/07Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Boa..
AQ
03/04Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Boa..
AQ
03/03ADAMIS PHARMACEUTICALS CORP : Change in Directors or Principal Officers (form 8-K)
AQ
03/01Adamis Pharmaceuticals Clinical Study Assessing Tempol for the Treatment of COVID-19 Su..
AQ
02/28Adamis Pharmaceuticals' Clinical Study Assessing Tempol for the Treatment of COVID-19 S..
AQ
02/21Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(4)
AQ
02/18ADAMIS PHARMACEUTICALS CORP : Amendment or Waiver to Code of Ethics (form 8-K)
AQ
02/18Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
02/07Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tem..
AQ
01/10ADAMIS PHARMACEUTICALS : Submits Fast Track Application to FDA for Tempol for the Treatmen..
PU
01/10ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
01/10Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatme..
AQ
01/05ADAMIS PHARMACEUTICALS : Delisting/Failure to Satisfy Listing Rule/Transfer of Listing - F..
PU
01/04ADAMIS PHARMACEUTICALS CORP : Notice of Delisting or Failure to Satisfy a Continued Listin..
AQ
2021Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Highe..
AQ
2021Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Highe..
AQ
2021ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
2021Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
GL
2021Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
GL
2021ADAMIS PHARMACEUTICALS : Announces Third Quarter 2021 Financial Results and Provides Corpo..
PU
2021ADAMIS PHARMACEUTICALS CORP : Results of Operations and Financial Condition (form 8-K)
AQ
2021ADAMIS : Q3 Earnings Snapshot
AQ
2021Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corp..
GL
2021ADAMIS PHARMACEUTICALS CORP Management's Discussion and Analysis of Financial Conditio..
AQ
2021Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
AQ
2021Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
GL
2021Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
GL
2021ADAMIS PHARMACEUTICALS : New High-Dose Naloxone Product for the Treatment of Opioid Overdo..
PU
2021ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
2021ADAMIS PHARMACEUTICALS : Receives FDA Approval for ZIMHI
AQ
2021ADAMIS PHARMACEUTICALS : Announces Appointment of Meera Desai, Ph.D., to Board of Director..
PU
2021ADAMIS PHARMACEUTICALS CORP : Change in Directors or Principal Officers, Regulation FD Dis..
AQ
2021Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
GL
2021ADAMIS PHARMACEUTICALS : Departure of Directors of Certain Officers; Election of Directors..
PU
2021ADAMIS PHARMACEUTICALS CORP : Change in Directors or Principal Officers (form 8-K)
AQ
2021Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in t..
GL
2021ADAMIS PHARMACEUTICALS : 8-K (Form 8-K)
PU
2021ADAMIS PHARMACEUTICALS CORP : Notice of Delisting or Failure to Satisfy a Continued Listin..
AQ
2021Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other..
GL
2021Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center ..
GL
2021ADAMIS HIGHLIGHTS NATIONAL INSTITUTE : A Potential Home Treatment for COVID-19”
GL
2021ADAMIS PHARMACEUTICALS CORP : Termination of a Material Definitive Agreement, Other Events..
AQ
2021ADAMIS PHARMACEUTICALS CORP : Entry into a Material Definitive Agreement, Completion of Ac..
AQ
2021ADAMIS PHARMACEUTICALS : Announces Agreement to Sell Portion of US Compounding Business
AQ
2021ADAMIS PHARMACEUTICALS CORP : Submission of Matters to a Vote of Security Holders (form 8-..
AQ
2021ADAMIS PHARMACEUTICALS : Announces Results of 2021 Annual Meeting of Stockholders
BU
2021ADAMIS PHARMACEUTICALS : Urges Stockholders to Vote to Reelect the Company's Board of Dire..
AQ
2021ADAMIS PHARMACEUTICALS : Urges Stockholders to Vote to Reelect the Company's Board of Dire..
BU
2021ADAMIS PHARMACEUTICALS CORP : Regulation FD Disclosure, Financial Statements and Exhibits ..
AQ
2021ADAMIS PHARMACEUTICALS : Sends Letter to Stockholders to Address Jerald A. Hammann's Costl..
AQ
2021ADAMIS PHARMACEUTICALS :  Adamis Sends Letter to Stockholders to Address Jerald A. Hammann..
BU
2021ADAMIS PHARMACEUTICALS : Sends Letter to Stockholders Regarding Its Strategic Focus on Tem..
BU
2021ADAMIS PHARMACEUTICALS : Files Definitive Proxy Statement and Sends Letter to Stockholders
BU
2021ADAMIS PHARMACEUTICALS : Provides Update on Clinical Trial Start-Up Progress for Tempol in..
AQ
2021Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment ..
GL
1  2  3  4Next
Upcoming event on ADAMIS PHARMACEUTICALS CORPORATION